Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Apr 29, 2026)

Reports
Leadership Changes
Filing Date
Filed April 29, 2026
Period End
April 28, 2026
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Apr ’20Apr ’20
  3. Material agreement8-K · Jul ’22Jul ’22
  4. Leadership change8-K · Feb ’25Feb ’25

Summary

Summary of the 8-K filed April 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K reporting a change in its Board of Directors.

Suketu Upadhyay, a current director, has informed the Board of his decision not to stand for re-election at the upcoming 2026 annual meeting of shareholders. This decision stems from Mr. Upadhyay's recent appointment as the forthcoming Chief Financial Officer of Incyte Corporation, a role that presents scheduling conflicts with his board responsibilities at Vertex.

Key Highlights

  1. Suketu Upadhyay, a current director, will not seek re-election at the 2026 annual meeting.
  2. Mr. Upadhyay's departure is due to scheduling conflicts arising from his new role as CFO of Incyte Corporation.
  3. The decision was not prompted by any disagreements with Vertex regarding its operations, policies, or practices.
  4. Mr. Upadhyay will continue to serve on the Board until the 2026 annual meeting.
  5. Vertex's Board intends to reduce its size to ten members following Mr. Upadhyay's departure.
  6. Mr. Upadhyay has been removed as a nominee from the Company's proxy materials for the 2026 Annual Meeting.
  7. The Company's slate of nominees remains otherwise unchanged, and previously cast proxies are still valid for other matters.

Frequently Asked Questions

  1. Why is Suketu Upadhyay leaving the Vertex Board?

    Mr. Upadhyay is not standing for re-election due to scheduling conflicts that have arisen from his new position as the forthcoming Chief Financial Officer of Incyte Corporation.

  2. Is Mr. Upadhyay's departure due to any issues with Vertex Pharmaceuticals?

    No, the filing explicitly states that Mr. Upadhyay's decision was not due to any disagreement with Vertex concerning its operations, policies, or practices. It is solely related to his new role at Incyte.

  3. What is the impact of Mr. Upadhyay's departure on the size of the Board?

    The Board of Directors intends to reduce its size to ten members following Mr. Upadhyay's departure after the 2026 annual meeting.

  4. Will my previously cast proxy vote be affected?

    Previously voted proxies remain valid for all matters and remaining nominees to be voted on at the 2026 Annual Meeting. However, votes cast specifically for Mr. Upadhyay will not be applicable as he is no longer a nominee.